It has to be said, I’ve never been one to crave the “next big gadget”, or to follow the crowd when it comes to following particular trends. But if I was to buy myself a stock as a long-overdue Christmas present to myself, I struggle to look further than one of the most popular among Fools and other investors alike – GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).
Yes, as it’s a gift to myself I could have speculated a little and moved for a slightly sexier small-cap growth stock, but there’s one thing that the pharma giant can offer my portfolio that most of my other holdings can’t: a great dividend. Since 2009, the dividend yield has hovered somewhere between 4.6% and 5.5%, with last year’s coming in at a very respectable 4.8%.
Now could be a good time to buy, too, in terms of the share price. It may have seen a steady rise to just under 1,500 since its October low of 1,324, but overall, the price is still down nearly 6% over the last 6 months. I could even consider that to be an early January bargain.
Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028 — more than double what it is today!
And with that kind of growth, this North American company stands to be the biggest winner.
Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…
We think it has the potential to become the next famous tech success story.
In fact, we think it could become as big… or even BIGGER than Shopify.
Chris Nials has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.